ANTI-DIABETIC COMPOUNDS

The present invention provides a FGF21 molecule covalently attached to the combining site of an antibody via a linker, wherein the linker is covalently attached to the side chain of a linking residue within FGF21. Various uses of the compounds are provided, including methods to prevent or treat diab...

Full description

Saved in:
Bibliographic Details
Main Authors VIOLAND, BERNARD NORMAN, PALANKI, MOORTHY SITHARAMAIAH SURIYANARAYANA, PARSONS, ERIN, KRISTEN, ISHINO, TETSUYA, DAS, TAPAN, KANTI, HODGE, TAMARA, SHAFER, LEVIN, NANCY, JANE
Format Patent
LanguageEnglish
French
Published 28.06.2012
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention provides a FGF21 molecule covalently attached to the combining site of an antibody via a linker, wherein the linker is covalently attached to the side chain of a linking residue within FGF21. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions. La présente invention concerne une molécule de FGF21 liée de façon covalente au site de combinaison d'un anticorps via un pont, ledit pont étant lié de façon covalente à la chaîne latérale d'un résidu de liaison au sein de FGF21. La présente invention concerne diverses utilisations des composés, y compris des méthodes de traitement prophylactique ou thérapeutique du diabète ou d'états pathologiques liés au diabète.
Bibliography:Application Number: WO2011IB54874